Pluro Fertility is a fertility healthtech startup based in India that partners with independent IVF specialists, handling non-clinical operations while doctors retain clinical autonomy.

This Startup Deep Dive explains what Pluro Fertility does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Pluro Fertility in Brief

• What it is: Pluro Fertility is an Indian IVF clinic partnership platform company based in Mumbai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Pluro works with independent IVF specialists through a clinical partnership model; doctors keep control of clinical decisions.
• It handles non-clinical operations such as finance, HR, technology, compliance, operations and marketing for partner clinics.
• Partner doctors, each with at least ten years of clinical experience, receive equity participation tied to Pluro's growth.
• Funding: Rs 125 crore (about $14-15 Mn; sources differ slightly on the dollar figure).

Pluro Fertility Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Pluro Fertility?

Pluro Fertility operates in the IVF clinic partnership platform space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Pluro Fertility.

• Pluro works with independent IVF specialists through a clinical partnership model; doctors keep control of clinical decisions.
• It handles non-clinical operations such as finance, HR, technology, compliance, operations and marketing for partner clinics.
• Partner doctors, each with at least ten years of clinical experience, receive equity participation tied to Pluro's growth.
• The stated goal is to build India's largest fertility chain.

The Origin Story of Pluro Fertility

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Dr. Jaydeep Tank, Dr. Parikshit Tank, Dr. Bhaskar Shah.
• It was founded in 2025 by Dr. Jaydeep Tank, Dr. Parikshit Tank and Dr. Bhaskar Shah.
• Jaydeep Tank is CEO and described as one of the earliest gynecologists to set up an IVF practice in India, having mentored over 20 specialists in setting up their own clinics.
• Parikshit Tank is an IVF specialist with over 80 peer-reviewed papers and four books.
• Bhaskar Shah is a healthcare administrator and promoter of Jupiter Hospitals, a listed chain.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the IVF clinic partnership platform sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2025: company founded in Mumbai.
• October 2025: Rs 125 crore Series A led by Bessemer Venture Partners at a Rs 1,000 crore valuation.
• Target of 25 fertility centres across India by March 2026 (company-stated; no report found confirming how many opened).
• Plan to scale to more than 100 clinics within three years (company-stated).

Pluro Fertility Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Series A (October 2025): reported Rs 125 crore led by Bessemer Venture Partners, with angels including Vikram Chatwal, Dharmil Sheth and Hardik Dedhia, Salil Musale, Shalibhadra Shah and Niket Shah, and Karan Kapur.

How Does Pluro Fertility Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• A partnership platform: independent IVF doctors keep their clinics and brand while Pluro runs back-office operations.
• Commercial terms with partner clinics were not disclosed in sources read.
• Doctors receive equity, aligning incentives across the network.

The Numbers: Pluro Fertility Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for Pluro Fertility were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for Pluro Fertility

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• About 27.5 million couples in India are affected by infertility (Bessemer).
• IVF cycles are expected to rise from roughly 300,000 in 2024 to 550,000 by 2030 (Bessemer).
• India has about 6,500 IVF centres, and nearly 90% are standalone clinics, so the market is highly fragmented.
• Patients in Tier 2 and 3 cities struggle to find consistent, standardised care.

Technology and Product at Pluro Fertility

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Capital is earmarked partly for technology and clinical capabilities in advanced reproductive science.

Team and Culture at Pluro Fertility

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Jaydeep Tank is co-founder and CEO.
• Each of the three founders has more than two decades of medical or healthcare leadership experience (Bessemer).

Pluro Fertility Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Pluro Fertility

• The plan depends on rapidly signing partner clinics to reach the stated centre targets.
• The sector is crowded with well-funded consolidators and has seen scrutiny of practices (sector review).
• No revenue or profit figures have been disclosed.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Pluro Fertility Growth Outlook: What to Watch

• Aim for 25 fertility centres by March 2026 and more than 100 clinics within three years (company-stated).
• Funds to be used for network expansion, technology and clinical capabilities.
• Bessemer frames it as a technology-enabled, single-specialty platform thesis.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Pluro Fertility can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Pluro Fertility Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Pluro Fertility

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Pluro Fertility.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Pluro Fertility

Studying a company in the IVF clinic partnership platform space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Pluro Fertility.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Pluro Fertility as a Startup

• Customer clarity: Can Pluro Fertility name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Pluro Fertility is part of India’s growing IVF clinic partnership platform ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Pluro Fertility FAQs: Frequently Asked Questions

What is Pluro Fertility?

Pluro Fertility is a fertility healthtech startup based in India that partners with independent IVF specialists, handling non-clinical operations while doctors retain clinical autonomy. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Pluro Fertility?

Pluro Fertility was founded by Dr. Jaydeep Tank, Dr. Parikshit Tank, Dr. Bhaskar Shah, and the company reports a founding year of 2025.

How much funding has Pluro Fertility raised?

Rs 125 crore (about $14-15 Mn; sources differ slightly on the dollar figure). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Pluro Fertility make money?

Pluro Fertility earns revenue from its IVF clinic partnership platform products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Pluro Fertility?

Reported rivals include Indira IVF, Nova IVF, Birla Fertility & IVF, Yellow Fertility & IVF. See the competitor comparison above for how they differ.

What are the main risks for Pluro Fertility?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Oziva — OZiva: HUL-backed nutrition brand hit Rs 258 Cr in FY25 | Pillow — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.